BioByte 057: Why invest in biotech, astrocytes in neuroinflammation, comp bio for novel CRISPR variants, life-extension drugs nearing approval
BioByte 056: the first approved CRISPR medicine, LLMs for genetic discovery, generative models for protein complexes, super-additivity in combination therapies, new NVIDIA-Genentech collaboration
Scaling Biology: Chris Gibson, Co-Founder and CEO of Recursion Pharmaceuticals
BioByte 55: a new chemistry foundation model, deep learning for affinity prediction, gliomas hijack neuronal processes, standardized single-cell data sets, Novartis calls on a Legend
BioByte 54: reprogramming therapies with mRNA, building bioweapons with chatbots, using active learning to traverse the chemical space, and more
BioByte 53: A new AlphaFold model, Future House to accelerate science, the shallow brain hypothesis, direct conversion of carbon to nitrogen, Lilly likes cardiovascular disease
BioByte 052: supercomputers and comp bio, foundation models for genes and cells, neural scaling of deep chemical models, ML-driven T cell infiltration prediction for solid tumors
BioByte 051: mapping the human body, foundation models, effective fundraising and rational molecular glue design
BioByte 050: multimodal biomedical AI from Amazon, AlphaFold for pandemic preparedness, a large pharma protein language model partnership
BioByte 049: atomwise focuses on pipeline, AI gets the american nobel prize, predicting transcriptional outcomes, nanopore protein sequencing detects all amino acids, deep learning for cryo-EM
BioByte 48: review of the obesity drugs, wearable non-invasive sensor for measuring female hormones, building a virtual cell, cracking the chemical code, is target-based drug discovery a waste of time
BioByte 047: multimodal AI for healthcare, tolerogenic vaccines, deciphering the lipidome, missense variant prediction, circRNAs in neurological disease, predicting TCR interactions
BioByte 046: pan-cancer AI models, benchmarks for single-cell LLMs, emergent properties of chemical language models, new astrocyte subtype uncovered
BioByte 045: partnership strategy user-manual biotechs, IRA's first drug list, epigenetic drivers of glioma, in vivo perturb-seq, synthetic data for clinical AI
BioByte 44: docking with AlphaFold, EvolutionaryScale, traversing chemical space, future prospects of LNPs, engineered antitumor bacteria, glial replacement in neurodegenration
BioByte 043: new implications for schizophrenia gene, what characterizes a cell type, multi-kilobase RNA editing, why age of menarche has dropped six years
BioByte 042: 36 billion compounds, genes that keep you alive, spatially-resolved sc-translatomics, predicting the effect of genetic variants on human proteins, myelin dynamics in multiple sclerosis
BioByte 041: NME generation: pharma vs. biotech, validation in AI drug discovery, whole body cellular mapping, deep learning for synergistic drug combos, AI x brain-computer interfaces
BioByte 040: controlling gene expression using bioelectronics, a new benchmark for multimodal biomedical AI, costs and causes of clinical failures in oncology, theories of cancer's origins
BioByte 39: the biomolecular atlas, SOTA deep learning for RNA structure prediction, applications of scRNA in drug development, AI x Bio Summit
BioByte 38: advances in medical AI, 100 pages on biosecurity, personalized cancer vaccines, self-delivering RNPs for gene editing, and more
BioByte 37: cameras to non-invasively measure neural activity, deep learning for spatial transcriptomics, whole body cellular mapping in mice, 100B-scale transformer for generative protein design
Decoding Bio Snapshot 2023
BioByte 036: the future of single cell bio, cell and gene therapy manufacturing, knowledge graphs for biomedical data, secret messaging with endogenous chemistry
BioByte 035: LLMs and biosecurity, AI-based design of PROTAC linkers, lessons in leadership and management in pharma R&D, transforming the dark chemical space of nature
BioByte 034: advances in prenatal gene therapy, the scoop on Laronde, the three waves of AI in bio, why gene therapies should go virus free, cell atlas of the human lungs
Decoding Biosecurity & Biodefense
BioByte 033: fragmentomics, mainstream gene therapies, the immune system and psychosis, herpes zoster vaccination and dementia, ProteinChat, human disease models
BioByte 032: AI and the overlooked stuff, base editing in mitochondria, ratio-tunable multi-gene expression, a brain-spine interface allows a man with tetraplegia to walk again
BioByte 031: the AI for chemistry revolution, safety in gene therapy, AlphaFold's structural shortcomings, mapping antisense oligos in the brain
BioByte 030: legislation for gene-edited crops, bio-developer survey, foundation model for single cell biology, first non-hormonal menopause drug
BioBye 029: solutions to RNA manufacturing, peptide-assisted genome editing, the biosignatures of dietary supplements, gene expression in the living human brain
BioByte 028: the bacteria that may be behind rheumatoid arthritis, how drug discovery companies use GPT, all you need to know about protein engineering, first in class vs best in class, and more...
BioByte 027: RL for multi-step chemistry, transcriptomic profiling for neurological diseases, the upending of cortical organizational theory, new funding models for biomedical innovation
BioByte 026: LLMs as "Intelligent Agents", pediatric cancer classifications, hypoimmune pancreatic islet cells, chromosome-arm-scale truncations from CRISPR
BioByte 025: ML for med chem intuition, co-opting a bacterial protein delivery system, de novo protein binder design for disordered proteins, neuroblastoma cell therapy breakthrough
BioByte 024: diffusion docking models, super evolution, organoid intelligence, frontiers in bio automation and cats
BioByte 023: gene drives, a new turing test for neuroAI, AlphaFold2 and protein-protein interactions, making science disruptive again
BioByte 022: human immunome project, male-derived egg cells, dual use of AI in drug discovery, are neurodegenerative diseases really just autoimmune diseases, and more
Request for feedback - Help us improve Decoding Bio
BioByte 021: the future of drug blockbusters, tiktok and protein design, crowdsourcing RNA degradation predictions, gripping integrins
BioByte 020: federal biodata infrastructure, deep learning brings light, using math to understand CAR-T, towards iPSC-derived ovarian biology, deep house on the waters of Hong Kong
BioByte 019: broken bacterial antibiotics pipelines, mini-organs on the rise, LTR retrotransposons in gene delivery, psychedelics that promote neuroplasticity, and more
BioByte 018: a biotech love poem, errors in high-impact genetics studies, human-level AI timelines, intratumor microbiota
BioByte 017
BioByte 016
Going Zero to One in TechBio: Five Lessons from Waypoint Bio CEO and Co-Founder, Xinchen Wang
BioByte 015
5 Bio Predictions for 2023
